News Abbisko Cayman Limited

Equities

2256

KYG0028A1085

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 08:08:20 12/03/2026 GMT			5-day change	1st Jan Change
12.40 ^HKD	-2.52%		+12.52%	-4.69%

03-11	Abbisko Drug Receives Rare Pediatric Designation in U.S.	MT
03-11	Abbisko Cayman says US FDA grants rare pediatric disease designation for FGFR2/3 inhibitor ABSK061	RE

All News

03-11	Abbisko Drug Receives Rare Pediatric Designation in U.S.	MT
03-11	Abbisko Cayman says US FDA grants rare pediatric disease designation for FGFR2/3 inhibitor ABSK061	RE
03-04	Abbisko Doses First Patient in Tumor Drug Trial	MT
03-03	Abbisko Cayman says CEO purchased total 45,000 shares of co at average price HK$11.26 per share	RE
03-03	Abbisko Profit Nearly Doubles in 2025	MT
03-02	Abbisko Cayman Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-11	Abbisko Unit Doses First U.S. Patient in Phase 1 Study of Liver Cancer Drug	MT
02-10	Abbisko Therapeutics Co., Ltd. Announces First Patient in the Expansion Part of A Global Phase I Study	CI
02-10	Abbisko Drug Secures Fast Track Designation in U.S.	MT
02-10	Abbisko Cayman says FDA grants fast track designation to Abbisko's irpagratinib	RE
01-13	Abbisko Cayman's new drug application for pimicotinib formally accepted by U.S. FDA	RE
01-13	Abbisko Tumor Treatment Pimicotinib Accepted for U.S. Review	MT
01-13	Abbisko Therapeutics Announces FDA Acceptance of the Nda for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor	CI
12-24	Abbisko Unit Gets China Investigational New Drug Clearance for Tumor Drug	MT
12-24	Abbisko Cayman says NMPA clears IND application for unit's Abbisko's Absk141	RE
12-22	Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor	GL
12-22	Abbisko Unit Gets China Nod for Tenosynovial Giant Cell Tumor	MT
12-22	Abbisko Cayman says Abbisko Therapeutics' CSF-1R inhibitor Pimicotinib approved by China NMPA	RE
12-16	Abbisko Unit Begins Phase 2 Dosing of ABSK061 for Achondroplasia	MT
12-02	Abbisko's IND Application for Cancer Therapy Cleared by U.S. FDA	MT
12-01	Abbisko Cayman says U.S. FDA clears IND application for ABSK141	RE
11-03	Abbisko Unit Doses First Patient in Lung Cancer Study	MT
15/09/25	Tranche Update on Abbisko Cayman Limited's Equity Buyback Plan announced on March 3, 2025.	CI
28/08/25	Abbisko Cayman subscribes $10 mln in callable zero coupon notes	RE
21/08/25	Abbisko Units Gets China Clearance for Lung Cancer Drug Application; Shares Jump 3%	MT